Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss  

作　　者：Wenyu Fu Meng Chen Kaidi Wang Yujianan Chen Yazhou Cui Yangli Xie Zi-Ning Lei Wenhuo Hu Guodong Sun Guiwu Huang Chaopeng He Jackie Fretz Aubryanna Hettinghouse Ronghan Liu Xianyi Cai Mingshuang Zhang Yuehong Chen Nan Jiang Minchun He Daniel HWiznia Huiyun Xu Zhe-Sheng Chen Lin Chen Kanglai Tang Hong Zhou Chuan-Ju Liu 

机构地区：[1]Department of Orthopaedics and Rehabilitation,Yale University School of Medicine,New Haven,CT,USA [2]Department of Orthopaedic Surgery,New York University Grossman School of Medicine,New York,NY,USA [3]Department of Orthopedics/Sports Medicine Center,Southwest Hospital,Third Military Medical University,Chongqing,China [4]Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan,Shandong,China [5]Laboratory of Wound Repair and Rehabilitation Medicine,State Key Laboratory of Trauma,Burns and Combined Injury,Daping Hospital,Army Medical University,Chongqing,China [6]Department of Pharmaceutical Science,College of Pharmacy and Health Sciences,St.John’s University,New York,NY,USA [7]Human Oncology and Pathogenesis Program,Memorial Sloan Kettering Cancer Center,Marie-Josée and Henry R.Kravis Center for Molecular Oncology,Memorial Sloan Kettering Cancer Center,New York,NY,USA [8]School of Life Sciences,Northwestern Polytechnical University,Xi’an,Shaanxi,China [9]Bone Research Program,ANZAC Research Institute,The University of Sydney,Sydney,NSW,Australia [10]Department of Cell Biology,New York University Grossman School of Medicine,New York,NY,USA

出　　处：《Cell Research》2025年第1期23-44,共22页细胞研究(英文版)

基　　金：supported partly by NIH research grants R01AR062207,R01AR061484,R01AR076900,R01AR078035 and R01NS070328.

摘　　要：Glucocorticoids(GCs)are the most prescribed anti-inflammatory and immunosuppressive drugs.However,their use is often limited by substantial side effects,such as GC-induced osteoporosis(GIO)with the underlying mechanisms still not fully understood.In this study,we identify Tau as a low-affinity binding receptor for GCs that plays a crucial role in GIO.Tau deficiency largely abolished bone loss induced by high-dose dexamethasone,a synthetic GC,in both inflammatory arthritis and GIO models.Furthermore,TRx0237,a Tau inhibitor identified from an FDA-approved drug library,effectively prevented GIO.Notably,combinatorial administration of TRx0237 and dexamethasone completely overcame the osteoporosis adverse effect of dexamethasone in treating inflammatory arthritis.These findings present Tau as a previously unrecognized GC receptor with low affinity,and provide potential strategies to mitigate a spectrum of GC-related adverse effects,particularly osteoporosis.

关 键 词：drugs PRESCRIBED AFFINITY 

分 类 号：R68[医药卫生—骨科学]